Is this the end for immunochemotherapy in relapsed/refractory chronic lymphocytic leukemia?

Affiliations

Comment

Tadeusz Robak. Leuk Lymphoma. 2023 May.

. 2023 May;64(5):907-909.

doi: 10.1080/10428194.2023.2188103. Epub 2023 Mar 10.

¹ Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland.

No abstract available

Comment on

Obinutuzumab plus bendamustine for relapsed/refractory chronic lymphocytic leukemia and predictive and prognostic impact of genetic alterations: the phase II GABRIELL study.
Bravo J, Baltasar Tello P, González Garcia E, Ríos Herranz E, Páyer AR, Terol Castera MJ, Champ D, Medina Perez A, Gironella M, Fernández Zarzoso M, Forés R, Delgado J, Garcia-Marco JA; GABRIELL Study Group/Investigators. Bravo J, et al. Leuk Lymphoma. 2023 May;64(5):913-926. doi: 10.1080/10428194.2023.2216327. Epub 2023 May 31. Leuk Lymphoma. 2023. PMID: 37255002 Clinical Trial.